Dashboard
Manage Tickers

GILDGILEAD SCIENCES, INC.

Nasdaq gilead.com


$ 79.17 $ 0.45 (0.57 %)    

Monday, 09-Sep-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 79.17
$ 79.15 x 100
$ 79.18 x 200
-- - --
$ 61.32 - $ 85.92
5,571,522
na
98.57B
$ 0.30
$ 93.52
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-23-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-04-2023 06-30-2023 10-Q
6 05-03-2023 03-31-2023 10-Q
7 02-22-2023 12-31-2022 10-K
8 11-02-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 02-23-2022 12-31-2021 10-K
12 11-03-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-26-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-06-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 02-27-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 02-27-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 02-24-2016 12-31-2015 10-K
36 11-04-2015 09-30-2015 10-Q
37 08-05-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 02-25-2015 12-31-2014 10-K
40 11-05-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
AstraZeneca Says Datopotamab Deruxtecan Sh...
09/09/2024 17:55:38

cantor-fitzgerald-reiterates-neutral-on-gilead-sciences-maintains-70-price-target
Cantor Fitzgerald Reiterates Neutral on Gi...
09/09/2024 15:38:20

Cantor Fitzgerald analyst Olivia Brayer reiterates Gilead Sciences (NASDAQ:GILD) with a Neutral and maintains $70 price target.

peering-into-gilead-sciencess-recent-short-interest
Peering Into Gilead Sciences's Recent Shor...
09/06/2024 19:00:21

gilead-to-present-new-trodelvy-data-at-the-iaslc-2024-world-conference-on-lung-cancer
Gilead To Present New Trodelvy Data At The...
09/05/2024 12:12:48

-Data Span Multiple Types of Lung Cancer and Lines of Therapy-Gilead Sciences, Inc. (NASDAQ:GILD) will present new data from th...

unveiling-10-analyst-insights-on-gilead-sciences
Unveiling 10 Analyst Insights On Gilead Sc...
09/04/2024 14:00:45

rbc-capital-maintains-sector-perform-on-gilead-sciences-raises-price-target-to-74
RBC Capital Maintains Sector Perform on Gi...
09/04/2024 13:15:08

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target...

mercks-death-cross-vs-gileads-golden-cross-pharma-giants-diverge-on-wall-street
Merck's Death Cross Vs. Gilead's Golden Cr...
09/03/2024 20:17:53

Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging techn...

gilead-sciences-options-trading-a-deep-dive-into-market-sentiment
Gilead Sciences Options Trading: A Deep Di...
09/03/2024 16:30:32

avenzo-therapeutics-announces-clinical-study-collaboration-with-gilead-sciences-to-evaluate-avzo-021-and-trodelvy-in-hrher2--metastatic-breast-cancer
Avenzo Therapeutics Announces Clinical Stu...
09/03/2024 13:03:49

AVZO-021, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Trodelvy (sacituzumab govitecan-hziy), ...

decoding-gilead-sciencess-options-activity-whats-the-big-picture
Decoding Gilead Sciences's Options Activit...
08/27/2024 18:00:52

100-invested-in-this-stock-20-years-ago-would-be-worth-900-today
$100 Invested In This Stock 20 Years Ago W...
08/22/2024 16:01:05

peering-into-gilead-sciencess-recent-short-interest
Peering Into Gilead Sciences's Recent Shor...
08/20/2024 16:00:15

pantherx-rare-partnering-with-gilead-sciences-for-distribution-of-livdelzi
Pantherx Rare Partnering With Gilead Scien...
08/16/2024 15:38:41

- Reuters 

gileads-ongoing-battle-against-counterfeit-hiv-medications-persists-with-new-lawsuit-seizes-750k-in-fake-drugs
Gilead's Ongoing Battle Against Counterfei...
08/16/2024 15:24:48

Gilead Sciences exposes a major counterfeiting ring led by Peter Khaim, involving tampered HIV medications resold from New York...

truist-securities-maintains-hold-on-gilead-sciences-raises-price-target-to-83
Truist Securities Maintains Hold on Gilead...
08/15/2024 13:09:45

Truist Securities analyst Robyn Karnauskas maintains Gilead Sciences (NASDAQ:GILD) with a Hold and raises the price target f...

fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal
FDA Approves Gilead's Seladelpar For Infla...
08/15/2024 13:09:17

FDA grants accelerated approval to Gilead's Livdelzi (seladelpar) for primary biliary cholangitis, offering new treatment o...

expert-outlook-gilead-sciences-through-the-eyes-of-8-analysts
Expert Outlook: Gilead Sciences Through Th...
08/15/2024 13:00:37

needham-reiterates-hold-on-gilead-sciences
Needham Reiterates Hold on Gilead Sciences
08/15/2024 11:34:57

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Hold.

fda-approves-gileads-livdelzi-for-primary-biliary-cholangitis
FDA Approves Gilead's Livdelzi For Primary...
08/14/2024 17:03:30

- Reuters Citing Co Website

rbc-capital-maintains-sector-perform-on-gilead-sciences-raises-price-target-to-72
RBC Capital Maintains Sector Perform on Gi...
08/09/2024 19:25:24

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION